EUCTR2016-001164-11-DE进行中（未招募）1 期
Open-label safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Informed consent signed.
- •2. Male or female subjects at least 18 years of age at Visit 1.
- •3. A diagnosis of CRPS according to the clinical diagnostic criteria recommended by the International Association for the Study of Pain (IASP; Budapest clinical criteria”).
- •4. Ongoing moderate to severe chronic pain, including a baseline current pain intensity score of 4 or greater using an 11-point NRS, referring to the CRPS-affected limb.
- •5. In stable treatment and follow-up therapy for CRPS for at least 1 month prior to allocation to treatment.
- •6. Women of child-bearing potential must have a negative urine (ß-HCG) pregnancy test and must be using 2 forms of medically
- •acceptable contraception.
- •7. Subjects must be able to communicate meaningfully, be able to differentiate with regard to location and intensity of the pain, and be able to answer the questions in the questionnaires used in this trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 258
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •1. Evidence of renal impairment (estimated glomerular filtration rate [eGFR] less than 60 mL/min/1.73 m2 or a urinary albumin creatinine Ratio greater than 30 mg/g). Note: If 2 consecutive laboratory tests
- •indicate eGFR levels greater or equal to 60 mL/min/1.73 m2 or a single
- •repeat laboratory test of the urinary albumin creatinine ratio is less than
- •30 mg/g during the enrollment period, the subject is eligible.
- •2. Serum calcium or magnesium outside of the central laboratory’s reference range.
- •3. Vitamin D deficiency, defined as a 25(OH)D level less than 30 ng/mL.
- •4. Corrected QT interval (QTcF) greater than 470 ms; serum potassium outside the central laboratory’s reference range; clinically unstable cardiac disease; evidence of complete left bundle branch block; complete atrioventricular block; history of Long QT Syndrome or a relative with this condition; or any other known risk factor for torsade de pointes.
- •5. Subjects receiving medications with a known risk of torsades de pointes within 7 days prior to allocation. Subjects receiving selective serotonin re-uptake inhibitor antidepressants (e.g., citalopram, escotalopram) or tricyclic antidepressants are eligible if the QT-interval
- •values do not meet the exclusion criteria, the medication was started at least 1 month prior to allocation, the dose is stable, and the dose is anticipated to remain stable until at least 4 days after the last infusion of IMP.
- •6. Anticipated requirement for treatment with oral or intravenous bisphosphonate for another condition, or administration of denosumab, or other drugs affecting bone turnover or bone metabolism within 6 months prior to Visit 1.
- •7. History of any allergic or hypersensitivity reaction to neridronic acid or other bisphosphonate, acetaminophen, or to vitamin D or calcium supplements.
- •8. Recent tooth extraction or other invasive dental procedure, unhealed or infected extraction site, or significant dental/periodontal disease that may predispose to need for tooth extraction or other invasive dental procedures during the trial.
- •9. Evidence of denture-related gum trauma or improperly fitting dentures causing injury.
- •10. Prior radiation therapy of the head or neck.
- •11. History of malignancy within 2 years prior to Visit 1, with the exception of basal cell carcinoma.
- •12. Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture, electromagnetic field treatment, or initiation/implementation of radiofrequency ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6 weeks prior to Visit 1.
- •13. Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within 2 years of Visit 1.
- •14. Any other severe medical condition, including severe depression, or any other severe mood disorder, that in the opinion of the investigator may affect efficacy or safety assessments or may compromise the subject’s safety during trial participation.
- •15. Women who are pregnant or breastfeeding.
- •16. Elevated aspartate aminotransferase or alanine aminotransferase greater than 2-fold upper limit of normal or current evidence of chronic liver disease.
研究者
相似试验
进行中（未招募）
1 期
Safety of intravenous neridronic acid in complex regional pain syndrome (CRPS)EUCTR2016-001164-11-PLGrünenthal GmbH225
已完成
1 期
A pilot study evaluating the safety of intravenously administered human amnion epithelial cells for the treatment of hepatic fibrosiscirrhosisliver fibrosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12616000437460Monash Health9
已完成
1 期
Amnion cells for the treatment of bronchopulmonary dysplasia in premature babiesBronchopulmonary dysplasiaACTRN12614000174684Monash Health Research Directorate6
已完成
3 期
Safety of Intravenous Neridronic Acid in CRPSComplex Regional Pain SyndromeNCT02972359Grünenthal GmbH580
已完成
2 期
Evaluating effect of intravenous midazolam on duration of spinal anesthesiaSpinal Anesthesia.Spinal anesthetics causing adverse effects in therapeutic useE938.7IRCT2014090716415N5Deputy of Research and technology of Isfahan University of Medical Sciences36